Skip to main content

Table 2 Patient characteristics according to anchor drug class from 2011 to 2016 (n = 1613)

From: Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database

Characteristics

NNRTI

(n = 325)

PI

(n = 564)

INSTI

(n = 723)

Age (years)

 Mean ± SD

48.0 ± 12.5

45.4 ± 12.3

41.9 ± 11.9

 Range

20–82

22–90

18–82

Age group (years)

 18–39

89 (27.4)

188 (33.3)

324 (44.8)

 40–59

166 (51.1)

291 (51.6)

324 (44.8)

 ≥ 60

70 (21.5)

85 (15.1)

75 (10.4)

Gender, male

299 (92.0)

488 (86.5)

683 (94.5)

AIDS-defining illnesses

154 (47.4)

263 (46.6)

280 (38.7)

HIV-related diseases

79 (24.3)

144 (25.5)

242 (33.5)

Hypertension

56 (17.2)

70 (12.4)

65 (9.0)

Dyslipidemia

97 (29.8)

151 (26.8)

134 (18.5)

Hepatitis B/C coinfection

48 (14.8)

69 (12.2)

103 (14.2)

Diabetes

85 (26.2)

131 (23.2)

135 (18.7)

Bone disorder

10 (3.1)

19 (3.4)

17 (2.4)

Vascular disease

8 (2.5)

13 (2.3)

15 (2.1)

Psychiatric disorders

29 (8.9)

61 (10.8)

84 (11.6)

Kidney disease

19 (5.8)

25 (4.4)

26 (3.6)

Malignancy

12 (3.7)

27 (4.8)

40 (5.5)

History of hospitalization

43 (13.2)

95 (16.8)

177 (24.5)

Year of ART initiation

 2011

5 (1.5)

6 (1.1)

1 (0.1)

 2012

27 (8.3)

65 (11.5)

17 (2.4)

 2013

72 (22.2)

115 (20.4)

51 (7.1)

 2014

181 (55.7)

290 (51.4)

290 (40.1)

 2015

26 (8.0)

53 (9.4)

181 (25.0)

 2016

14 (4.3)

35 (6.2)

183 (25.3)

  1. NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, INSTI integrase strand transfer inhibitor, SD standard deviation, HIV human immunodeficiency virus, ART antiretroviral therapy
  2. Values are expressed as number (percentage) unless specified otherwise
  3. One patient prescribed an entry inhibitor was excluded from the table